Shares of Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA – Get Free Report) have been given a consensus rating of “Moderate Buy” by the six brokerages that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating and five have issued a buy rating on the company. The average 1-year price target among brokers that have covered the stock in the last year is $6.67.
A number of analysts have recently weighed in on IPHA shares. HC Wainwright reissued a “buy” rating on shares of Innate Pharma in a research report on Monday, September 21st. Leerink Partners upgraded shares of Innate Pharma from a “market perform” rating to an “outperform” rating and set a $4.00 price target for the company in a research note on Tuesday, August 11th. Citigroup raised shares of Innate Pharma from a “buy” rating to an “outperform” rating in a report on Tuesday, August 11th. BTIG Research reaffirmed a “buy” rating on shares of Innate Pharma in a report on Thursday, November 5th. Finally, UBS Group reiterated a “buy” rating on shares of Innate Pharma in a research note on Tuesday, August 11th.
Get Our Latest Stock Analysis on Innate Pharma
Innate Pharma Stock Down 22.6%
Shares of IPHA opened at $1.03 on Thursday. The business’s 50 day moving average is $1.57 and its two-hundred day moving average is $1.69. Innate Pharma has a 52-week low of $1.00 and a 52-week high of $2.71.
About Innate Pharma
Innate Pharma is a clinical-stage biotechnology company based in Marseille, France. It develops immunotherapies for cancer, with research focused on harnessing the body’s innate immune system to recognize and attack tumor cells. The company’s work includes antibody-based treatments and cell therapies, with investigational candidates being studied for blood cancers and other malignancies. Its pipeline includes lacutamab, an antibody candidate targeting KIR3DL2, and programs developed with pharmaceutical partners.
See Also
- Five stocks we like better than Innate Pharma
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Innate Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innate Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
